CTTH (CTT Pharmaceutical Holdings) EBITDA: $-0.15 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CTT Pharmaceutical Holdings EBITDA?

CTT Pharmaceutical Holdings CTTH -0.13% EBITDA is $-0.15 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

CTT Pharmaceutical Holdings's EBITDA for the six months ended in Dec. 2025 was $-0.15 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.15 Mil.

During the past 3 years, the average EBITDA Growth Rate was 39.60% per year. During the past 5 years, the average EBITDA Growth Rate was 4.40% per year. During the past 10 years, the average EBITDA Growth Rate was 20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of CTT Pharmaceutical Holdings was 78.80% per year. The lowest was -235.30% per year. And the median was 0.40% per year.

CTT Pharmaceutical Holdings's EBITDA per Share for the twelve months ended in Dec. 2025 was $-0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00.

During the past 3 years, the average EBITDA per Share Growth Rate was 80.60% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 53.50% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 50.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of CTT Pharmaceutical Holdings was 92.50% per year. The lowest was -71.00% per year. And the median was 16.65% per year.

CTT Pharmaceutical Holdings  (OTCPK:CTTH) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


CTT Pharmaceutical Holdings EBITDA Related Terms


CTT Pharmaceutical Holdings EBITDA Historical Data

* Premium members only.

The historical data trend for CTT Pharmaceutical Holdings's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CTT Pharmaceutical Holdings EBITDA Chart

CTT Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec24 Dec25
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.67 -1.45 -0.24 -0.15

CTT Pharmaceutical Holdings Semi-Annual Data
Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec24 Dec25
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.67 -1.45 -0.24 -0.15

CTTH vs BUDZ, SBFM, PRFX: EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTT Pharmaceutical Holdings EV-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CTT Pharmaceutical Holdings's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

CTT Pharmaceutical Holdings's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

CTT Pharmaceutical Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, CTT Pharmaceutical Holdings's EBITDA was $-0.15 Mil.

CTT Pharmaceutical Holdings's EBITDA for the quarter that ended in Dec. 2025 is calculated as

CTT Pharmaceutical Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2025, CTT Pharmaceutical Holdings's EBITDA was $-0.15 Mil.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $-0.15 Mil mean?
CTT Pharmaceutical Holdings (CTTH) has a EBITDA of $-0.15 Mil as of Dec. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on CTT Pharmaceutical Holdings.
Is CTT Pharmaceutical Holdings' EBITDA too high?
CTT Pharmaceutical Holdings' current EBITDA is $-0.15 Mil.
How does CTT Pharmaceutical Holdings' EBITDA compare to BUDZ and SBFM?
CTT Pharmaceutical Holdings' EBITDA of $-0.15 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Drug Manufacturers company?
A good EBITDA depends on the Drug Manufacturers industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on CTT Pharmaceutical Holdings. CTT Pharmaceutical Holdings's current EBITDA is $-0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current EBITDA of $-0.15 Mil. The current EBITDA is $-0.15 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current EBITDA is $-0.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CTT Pharmaceutical Holdings Business Description

Address 3853 Northdale Boulevard, Suite 268, Tampa, FL, USA, 33624
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.